loading
Precedente Chiudi:
$9.54
Aprire:
$10
Volume 24 ore:
72,265
Relative Volume:
1.73
Capitalizzazione di mercato:
$273.90M
Reddito:
-
Utile/perdita netta:
$-102.09M
Rapporto P/E:
-9.5238
EPS:
-1.05
Flusso di cassa netto:
$-108.72M
1 W Prestazione:
+0.10%
1M Prestazione:
+7.76%
6M Prestazione:
+127.53%
1 anno Prestazione:
+117.32%
Intervallo 1D:
Value
$9.51
$10.00
Intervallo di 1 settimana:
Value
$9.51
$10.26
Portata 52W:
Value
$2.2045
$12.78

Dbv Technologies Adr Stock (DBVT) Company Profile

Name
Nome
Dbv Technologies Adr
Name
Telefono
33(0)155427878
Name
Indirizzo
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Name
Dipendente
109
Name
Cinguettio
@dbvtechnologies
Name
Prossima data di guadagno
2024-07-29
Name
Ultimi documenti SEC
Name
DBVT's Discussions on Twitter

Confronta DBVT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
DBVT
Dbv Technologies Adr
10.00 273.62M 0 -102.09M -108.72M -1.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-29 Ripresa Goldman Sell
2023-01-04 Aggiornamento Societe Generale Hold → Buy
2022-12-16 Downgrade Goldman Neutral → Sell
2022-05-10 Downgrade Goldman Buy → Neutral
2021-09-14 Aggiornamento Societe Generale Hold → Buy
2021-01-22 Downgrade Societe Generale Hold → Sell
2020-11-02 Aggiornamento Societe Generale Sell → Hold
2020-08-06 Downgrade Societe Generale Buy → Sell
2020-08-05 Reiterato H.C. Wainwright Buy
2020-03-17 Downgrade Stifel Buy → Hold
2020-01-09 Aggiornamento Stifel Hold → Buy
2019-12-16 Iniziato Citigroup Buy
2019-09-05 Ripresa Morgan Stanley Equal-Weight
2019-06-17 Iniziato Goldman Buy
2018-12-20 Downgrade Barclays Overweight → Equal Weight
2018-12-20 Downgrade BofA/Merrill Buy → Underperform
2018-12-20 Downgrade Jefferies Buy → Hold
2018-12-20 Downgrade Stifel Buy → Hold
2017-10-31 Aggiornamento Societe Generale Sell → Hold
2017-10-24 Downgrade Societe Generale Buy → Sell
2017-10-23 Downgrade Morgan Stanley Overweight → Equal-Weight
2017-06-23 Iniziato Deutsche Bank Buy
2017-03-16 Aggiornamento Societe Generale Hold → Buy
2016-09-26 Iniziato JMP Securities Mkt Outperform
2015-12-03 Iniziato Barclays Overweight
2015-10-23 Iniziato BofA/Merrill Buy
Mostra tutto

Dbv Technologies Adr Borsa (DBVT) Ultime notizie

pulisher
Aug 19, 2025

Published on: 2025-08-19 16:04:03 - Newser

Aug 19, 2025
pulisher
Aug 16, 2025

DBV Technologies S.A. Depositary Receipt Moves Into Bullish Territory Based on MACD2025 Market Trends & Precise Swing Trade Alerts - metal.it

Aug 16, 2025
pulisher
Aug 16, 2025

DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Aug 16, 2025
pulisher
Aug 15, 2025

European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest

Aug 15, 2025
pulisher
Aug 09, 2025

European ADRs Edge Higher While Sector Winners And Losers Diverge - Finimize

Aug 09, 2025
pulisher
Aug 06, 2025

Does DBV Technologies S.A. Depositary Receipt fit your quant trading modelAlpha Generation Strategy with Low Volatility - Newser

Aug 06, 2025
pulisher
Aug 02, 2025

HC Wainwright Lowers Earnings Estimates for DBV Technologies - Defense World

Aug 02, 2025
pulisher
Aug 01, 2025

DBV Technologies Maintains Buy Rating with €6.00 Target from Kepler Capital's Justine Telliez - AInvest

Aug 01, 2025
pulisher
Jul 29, 2025

DBV Technologies Announces Filing of 2025 Half-Year Report - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report - GlobeNewswire

Jul 29, 2025
pulisher
Jul 29, 2025

DBV Technologies S.A. - Via Ritzau

Jul 29, 2025
pulisher
Jul 29, 2025

DBV Technologies Releases Latest Financial Report: Food Allergy Treatment Progress Updates Inside - Stock Titan

Jul 29, 2025
pulisher
Jul 29, 2025

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results - GlobeNewswire

Jul 29, 2025
pulisher
Jul 28, 2025

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - The Manila Times

Jul 28, 2025
pulisher
Jul 28, 2025

DBV Technologies Liquidity Contract Update: Over €3M in Trading Volume Reveals Market Activity - Stock Titan

Jul 28, 2025
pulisher
Jul 27, 2025

DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Tuesday - Defense World

Jul 27, 2025
pulisher
Jul 25, 2025

DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Average PT from Analysts - Defense World

Jul 25, 2025
pulisher
Jul 24, 2025

European ADRs Inch Higher As Drugmakers Shine - Finimize

Jul 24, 2025
pulisher
Jul 22, 2025

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

DBV Technologies Taps Healthcare Veteran as CHRO to Drive Commercial Evolution - Stock Titan

Jul 22, 2025
pulisher
Jul 20, 2025

What analysts say about DBV Technologies S.A. Depositary Receipt stockHigh-impact stock picks - Autocar Professional

Jul 20, 2025
pulisher
Jul 14, 2025

European Stocks In The US Finish With A Modest Rebound - Finimize

Jul 14, 2025
pulisher
Jul 13, 2025

Analysts Are Bullish on Top Healthcare Stocks: Neurogene (NGNE), Cogent Biosciences (COGT) - The Globe and Mail

Jul 13, 2025
pulisher
Jul 10, 2025

European ADRs Climb As Verona Pharma Leads Gains - Finimize

Jul 10, 2025
pulisher
Jul 09, 2025

European ADRs Climb As Sequans Leads The Charge - Finimize

Jul 09, 2025
pulisher
Jul 07, 2025

DBV Technologies’ SWOT analysis: peanut allergy patch stock poised for growth - Investing.com India

Jul 07, 2025
pulisher
Jul 05, 2025

DBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street Zen - Defense World

Jul 05, 2025
pulisher
Jul 01, 2025

European Stocks Climb As ADRs Post Gains - Finimize

Jul 01, 2025
pulisher
Jul 01, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jul 01, 2025
pulisher
Jun 30, 2025

European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest

Jun 30, 2025
pulisher
Jun 28, 2025

Lifesci Capital Upgrades DBV Technologies (NASDAQ:DBVT) to Strong-Buy - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

European Biopharma Leads Gains In ADR Market Surge - Finimize

Jun 27, 2025
pulisher
Jun 27, 2025

European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest

Jun 27, 2025
pulisher
Jun 26, 2025

European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize

Jun 26, 2025
pulisher
Jun 26, 2025

DBV Technologies stock holds steady as JMP reiterates $21 price target - Investing.com

Jun 26, 2025
pulisher
Jun 25, 2025

Breakthrough Peanut Allergy Treatment Enters Critical Phase 3 Trial for Toddlers as Young as 12 Months - Stock Titan

Jun 25, 2025
pulisher
Jun 21, 2025

European ADRs Dip As Evaxion And Grifols Climb - Finimize

Jun 21, 2025
pulisher
Jun 18, 2025

European ADRs Dip While Biotech And Energy See Gains - Finimize

Jun 18, 2025
pulisher
Jun 16, 2025

European Stocks Shine As ADRs Climb Higher - Finimize

Jun 16, 2025

Dbv Technologies Adr Azioni (DBVT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Dbv Technologies Adr Azioni (DBVT) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Mohideen Pharis
Chief Medical Officer
May 22 '25
Sale
1.84
397
730
110,113
Mohideen Pharis
Chief Medical Officer
Jan 30 '25
Sale
0.85
600
510
110,510
Mohideen Pharis
Chief Medical Officer
Nov 25 '24
Sale
0.57
565
322
111,110
Mohideen Pharis
Chief Medical Officer
Nov 22 '24
Sale
0.53
342
181
111,675
Mohideen Pharis
Chief Medical Officer
Nov 21 '24
Sale
0.54
2,350
1,269
112,017
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Capitalizzazione:     |  Volume (24 ore):